↓ Skip to main content

Dove Medical Press

Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials

Overview of attention for article published in Drug Design, Development and Therapy, September 2017
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (52nd percentile)
  • Above-average Attention Score compared to outputs of the same age and source (53rd percentile)

Mentioned by

policy
1 policy source

Citations

dimensions_citation
35 Dimensions

Readers on

mendeley
52 Mendeley
Title
Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials
Published in
Drug Design, Development and Therapy, September 2017
DOI 10.2147/dddt.s146286
Pubmed ID
Authors

Manni Wang, Xuelei Ma, Linghong Guo, Fan Xia

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 52 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 52 100%

Demographic breakdown

Readers by professional status Count As %
Other 7 13%
Student > Bachelor 7 13%
Researcher 6 12%
Student > Postgraduate 4 8%
Student > Master 3 6%
Other 9 17%
Unknown 16 31%
Readers by discipline Count As %
Medicine and Dentistry 20 38%
Biochemistry, Genetics and Molecular Biology 5 10%
Pharmacology, Toxicology and Pharmaceutical Science 4 8%
Mathematics 1 2%
Immunology and Microbiology 1 2%
Other 1 2%
Unknown 20 38%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 August 2019.
All research outputs
#8,626,132
of 25,604,262 outputs
Outputs from Drug Design, Development and Therapy
#650
of 2,271 outputs
Outputs of similar age
#125,694
of 325,038 outputs
Outputs of similar age from Drug Design, Development and Therapy
#18
of 47 outputs
Altmetric has tracked 25,604,262 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,271 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has gotten more attention than average, scoring higher than 66% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 325,038 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 52% of its contemporaries.
We're also able to compare this research output to 47 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 53% of its contemporaries.